963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
| Autor: | Mora, J., Bear, M., Chan, G., Morgenstern, D.A., Nysom, K., Tornøe, K., Losic, N., Kushner, B. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S833-S833 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|